Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation

被引：24
作者：
Nozzoli, C
Bartolozzi, B
Guidi, S
Orsi, A
Vannucchi, AM
Leoni, F
Bosi, A
机构：
[1] Univ Florence, BMT Unit, Dept Hematol, I-50121 Florence, Italy
[2] Careggi Hosp, Dept Microbiol, Florence, Italy
来源：
LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 01期
关键词：
cidofovir; CNS involvement; Epstein-Barr virus reactivation; intrathecal chemotherapy; post-transplant lymphoproliferative disorder; rituximab;
D O I：
10.1080/10428190500254208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Post-transplant lymphoproliferative disorders (PTLD) represent an heterogeneous group of abnormal lymphoid proliferation related to Epstein-Barr virus (EBV) reactivation that arise early after allogeneic hematopoietic stem cell transplant (HSCT). PLTD with central nervous system (CNS) involvement has been reported in few cases. We describe the case of a 31-year-old-man who developed an EBV-related PTLD with CNS involvement 2 months after an allogeneic unrelated HSCT for acute myeloid leukemia in first complete remission who was successfully treated with rituximab, cidofovir and intrathecal infusion of methotrexate and methylprednisolone.
引用
收藏
页码：167 / 169
页数：3
相关论文
共 14 条
[1]   Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies [J].
Abdulkarim, B ;
Sabri, S ;
Zelenika, D ;
Deutsch, E ;
Frascogna, V ;
Klijanienko, J ;
Vainchenker, W ;
Joab, I ;
Bourhis, J .
ONCOGENE, 2003, 22 (15) :2260-2271
[2]   Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome [J].
Benkerrou, M ;
Jais, JP ;
Leblond, V ;
Durandy, A ;
Sutton, L ;
Bordigoni, P ;
Garnier, JL ;
Le Bidois, J ;
Le Deist, F ;
Blanche, S ;
Fischer, A .
BLOOD, 1998, 92 (09) :3137-3147
[3]   Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma [J].
Chua, SL ;
Seymour, JF ;
Streater, J ;
Wolf, MM ;
Januszewicz, EH ;
Prince, HM .
LEUKEMIA & LYMPHOMA, 2002, 43 (09) :1783-1788
[4]   Immunotherapy for Epstein-Barr virus-associated tumors [J].
Comito, MA ;
Sun, Q ;
Lucas, KG .
LEUKEMIA & LYMPHOMA, 2004, 45 (10) :1981-1987
[5]  
Curtis RE, 1999, BLOOD, V94, P2208
[6]   Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation [J].
Gruhn, B ;
Meerbach, A ;
Häfer, R ;
Zell, R ;
Wutzler, P ;
Zintl, F .
BONE MARROW TRANSPLANTATION, 2003, 31 (11) :1023-1025
[7]   Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement [J].
Hänel, M ;
Fiedler, F ;
Thorns, C .
ONKOLOGIE, 2001, 24 (05) :491-494
[8]  
Ifthikharuddin JJ, 2000, AM J HEMATOL, V65, P171, DOI 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO
[9]  
2-Z
[10]   High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment [J].
Juvonen, E ;
Aalto, SM ;
Tarkkanen, J ;
Volin, L ;
Mattila, PS ;
Knuutila, S ;
Ruutu, T ;
Hedman, K .
BONE MARROW TRANSPLANTATION, 2003, 32 (01) :97-102
12